Shares of Axsome Therapeutics Inc (NASDAQ:AXSM) have been given an average rating of “Buy” by the seven brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $24.75.
Several equities analysts have issued reports on AXSM shares. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Axsome Therapeutics in a research report on Wednesday, December 5th. Cantor Fitzgerald set a $16.00 price target on shares of Axsome Therapeutics and gave the company a “buy” rating in a research report on Monday, December 10th. ValuEngine cut shares of Axsome Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. LADENBURG THALM/SH SH restated a “positive” rating and issued a $45.00 price target (up from $34.00) on shares of Axsome Therapeutics in a research report on Monday, January 7th. Finally, BTIG Research upped their price target on shares of Axsome Therapeutics to $20.00 and gave the company a “buy” rating in a research report on Tuesday, January 8th.
A number of hedge funds and other institutional investors have recently made changes to their positions in AXSM. Alethea Capital Management LLC increased its position in Axsome Therapeutics by 65.9% in the 4th quarter. Alethea Capital Management LLC now owns 908,429 shares of the company’s stock valued at $2,562,000 after acquiring an additional 360,986 shares during the period. Millennium Management LLC bought a new stake in shares of Axsome Therapeutics in the 4th quarter valued at $871,000. Sio Capital Management LLC boosted its stake in shares of Axsome Therapeutics by 115.5% in the 3rd quarter. Sio Capital Management LLC now owns 416,458 shares of the company’s stock valued at $1,437,000 after purchasing an additional 223,168 shares during the last quarter. Worth Venture Partners LLC bought a new stake in shares of Axsome Therapeutics in the 3rd quarter valued at $138,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Axsome Therapeutics in the 4th quarter valued at $98,000. Hedge funds and other institutional investors own 12.84% of the company’s stock.
Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.01. As a group, research analysts expect that Axsome Therapeutics will post -1.1 earnings per share for the current fiscal year.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.
Featured Article: Channel Trading
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.